Akero Therapeutics' drug, efruxifermin, demonstrated significant reduction in liver scarring after nearly two years in a mid-stage study for metabolic dysfunction-associated steatohepatitis (MASH) patients. The drug showed superior benefits compared to other treatments, with potential peak sales of $2-3 billion. Confirmation in a late-stage trial is required. NASH affects over 17 million Americans, with no approved drugs currently available.
In eine andere Sprache
aus dem Quellinhalt
www.medscape.com
Wichtige Erkenntnisse aus
by Leroy um www.medscape.com 03-04-2024
https://www.medscape.com/s/viewarticle/akeros-fatty-liver-disease-drug-lessens-scarring-mid-stage-2024a1000450Tiefere Fragen